Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Pharma
GSK to seek FDA approval for Jemperli in high-profile cancer use
Jemperli’s potential in the small rectal cancer indication drew public attention in 2022 with a 100% complete response rate from a small study.
Angus Liu
Jul 13, 2026 10:50am
FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
Jul 10, 2026 10:55am
Fosun Pharma plots global push, fueled by Alzheimer’s deals
Jun 25, 2026 7:00pm
Nature retracts provocative PD-1 time-of-day study
Jun 24, 2026 11:00am
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
May 27, 2026 11:25am
Novo's Indiana plant claims another victim in Incyte's PD-1
Mar 9, 2026 10:45am
